Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank McCormick

Showing results (11-20 of 303) with videos related to

Pageof 31
Sort By:
Cancer Biology & Therapy|February 5, 2008
Success and failure on the ras pathwayFrank McCormick
Current Opinion in Genetics & Development|January 18, 2011
Mutant onco-proteins as drug targets: successes, failures, and future prospectsFrank McCormick
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
KRAS as a Therapeutic TargetFrank McCormick
The Biochemical Journal|February 2, 2019
Progress in targeting RAS with small molecule drugsFrank McCormick
Oncogene|November 22, 2005
Future prospects for oncolytic therapyFrank McCormick
DNA and Cell Biology|August 7, 2002
MDMX inhibits the p300/CBP-mediated acetylation of p53Peter Sabbatini, Frank McCormick
Genes & Development|April 19, 2021
SPRED proteins and their roles in signal transduction, development, and malignancyClaire Lorenzo, Frank McCormick
Clinical and Translational Medicine|May 6, 2017
ETS-targeted therapy: can it substitute for MEK inhibitors?Osamu Tetsu, Frank McCormick
Cancer Cell|April 5, 2003
Proliferation of cancer cells despite CDK2 inhibitionOsamu Tetsu, Frank McCormick
Virology Journal|July 10, 2010
Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cellsCynthia Lyle, Frank McCormick
Pageof 31

Showing results (11-20 of 303) with videos related to

Sort By:
Pageof 31
Cancer Biology & Therapy|February 5, 2008
Success and failure on the ras pathwayFrank McCormick
Current Opinion in Genetics & Development|January 18, 2011
Mutant onco-proteins as drug targets: successes, failures, and future prospectsFrank McCormick
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
KRAS as a Therapeutic TargetFrank McCormick
The Biochemical Journal|February 2, 2019
Progress in targeting RAS with small molecule drugsFrank McCormick
Oncogene|November 22, 2005
Future prospects for oncolytic therapyFrank McCormick
DNA and Cell Biology|August 7, 2002
MDMX inhibits the p300/CBP-mediated acetylation of p53Peter Sabbatini, Frank McCormick
Genes & Development|April 19, 2021
SPRED proteins and their roles in signal transduction, development, and malignancyClaire Lorenzo, Frank McCormick
Clinical and Translational Medicine|May 6, 2017
ETS-targeted therapy: can it substitute for MEK inhibitors?Osamu Tetsu, Frank McCormick
Cancer Cell|April 5, 2003
Proliferation of cancer cells despite CDK2 inhibitionOsamu Tetsu, Frank McCormick
Virology Journal|July 10, 2010
Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cellsCynthia Lyle, Frank McCormick
Pageof 31